Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of sublingual house dust mite allergen tablets in allergic asthma
2013-000487-28Phase 2Completed
- Sponsor
- Stallergenes Greer
- Start
- Apr 2013
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of House dust mite allergen extract in allergic asthma and house dust mite allergy (4 arms), sponsored by Stallergenes Greer. Primary endpoint: Change of ACT Score from baseline. Started Apr 2013; status: completed.
02
Drugs
House dust mite allergen extract
03
Conditions
allergic asthmahouse dust mite allergy
Beyond the preview
Go deeper on 2013-000487-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000487-28.